Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928294 | 0.87 | EGFR (0.37) | ABL1BRAFPDE8B | |
| SCHEMBL4010740 | 0.85 | SYK (0.37) | ABL1BRAF | |
| SCHEMBL18833080 | 0.84 | EGFR (0.30) | ABL1 | |
| SCHEMBL3926435 | 0.83 | CHEK2 (0.32) | — | |
| SCHEMBL13375054 | 0.81 | ABL1 (0.33) | ABL1 | |
| SCHEMBL5951727 | 0.79 | EGLN1 (0.34) | ABL1 | |
| SCHEMBL3926000 | 0.77 | FGFR1 (0.37) | ABL1 | |
| SCHEMBL3924589 | 0.77 | FGFR1 (0.38) | — | |
| SCHEMBL5952627 | 0.76 | ABL1 (0.32) | ABL1 | |
| SCHEMBL3928184 | 0.75 | FGFR1 (0.36) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
| EP-2041119-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | Aventis Pharma S.A. (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003857-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | RB1, CCNI, CDK2 | ABL1 226/4885BRAF 56/4885PDE8B 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.